Carlos López Chang

Creatine is known for building muscle and improving athletic performance. A new UCLA study just found it does something completely different—it powers the immune cells that direct your body's cancer-fighting response. Researchers published the findings in iScience after studying both mouse models and human cells. The discovery builds on earlier work showing creatine fuels killer T cells that attack tumors directly. Now they've found creatine also energizes dendritic cells—the immune cells that capture tumor fragments and train T cells where to strike. Most cancer immunotherapies target killer T cells directly, but only 20-40% of patients respond. The limitation isn't the T cells themselves. It's the dendritic cells upstream that activate and direct them. The research team started by examining which metabolic genes were most active in dendritic cells that had infiltrated tumors in mice. One gene stood out: the creatine transporter, which pulls creatine into cells. It was markedly elevated in tumor-infiltrating dendritic cells compared to those in healthy tissue. To test whether this mattered, they engineered dendritic cells that couldn't transport creatine. These cells showed impaired survival, reduced activation, and weakened ability to prime T cells for tumor response. When grown alongside T cells in a lab dish, those T cells divided less and produced fewer cancer-fighting signaling molecules. Then they tested the opposite intervention—increasing creatine instead of removing it. Daily creatine injections in melanoma-bearing mice significantly slowed tumor growth and boosted both the number and activation of dendritic cells infiltrating tumors. The creatine-treated dendritic cells produced higher levels of chemical signals that recruit additional immune cells to the tumor site. Metabolomics analysis revealed the mechanism: creatine supplementation raised intracellular ATP levels in dendritic cells. ATP is the energy currency cells use to power nearly every function. Creatine acts like a battery—storing and releasing energy on demand, helping dendritic cells maintain stable energy levels even when competing with fast-growing tumor cells for nutrients. The effect extended to human cells. Creatine treatment enhanced activation of human monocyte-derived dendritic cells—the type often used in dendritic cell cancer vaccines—and improved their ability to stimulate human T cells against cancer-associated targets. The findings suggest incorporating creatine during manufacturing of dendritic cell vaccines may boost their therapeutic potency. More broadly, they reveal that creatine doesn't just help the immune cells fighting cancer directly—it energizes the infrastructure that supports and guides them. Immuotherapy works for some patients but fails for most. The difference may come down to whether dendritic cells can maintain enough energy to properly activate the T cell response. Creatine supplementation addresses that metabolic constraint. A supplement taken by millions for muscle growth and athletic performance turns out to support immune cell function at a fundamental metabolic level—powering both the killer T cells that attack tumors and the dendritic cells that train them where to go.